These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29794817)

  • 1. Doravirine: a review.
    Colombier MA; Molina JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):308-314. PubMed ID: 29794817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doravirine: A Return of the NNRTI Class?
    Blevins SR; Hester EK; Chastain DB; Cluck DB
    Ann Pharmacother; 2020 Jan; 54(1):64-74. PubMed ID: 31416335
    [No Abstract]   [Full Text] [Related]  

  • 4. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
    Thompson M; Orkin C; Molina JM; Sax P; Cahn P; Squires K; Xu X; Rodgers A; Kumar S; Teppler H; Martin E; Hanna G; Hwang C
    Clin Infect Dis; 2020 Mar; 70(7):1336-1343. PubMed ID: 31121013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
    Wong A; Goldstein D; Mallolas J; DeJesus E; Johnson M; Molina JM; Pozniak A; Rodgers A; Teal V; Hepler D; Kumar S; Sklar P; Hanna GJ; Hwang C; Badshah C; Teppler H
    J Acquir Immune Defic Syndr; 2019 Dec; 82(4):e47-e49. PubMed ID: 31425317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of Doravirine: From Bench to Patients.
    Hwang C; Lai MT; Hazuda D
    ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.
    Anderson MS; Gilmartin J; Fan L; Yee KL; Kraft WK; Triantafyllou I; Reitmann C; Guo Y; Liu R; Iwamoto M
    Antivir Ther; 2019; 24(6):443-450. PubMed ID: 31433304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Talwani R; Temesgen Z
    Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
    Schürmann D; Sobotha C; Gilmartin J; Robberechts M; De Lepeleire I; Yee KL; Guo Y; Liu R; Wagner F; Wagner JA; Butterton JR; Anderson MS
    AIDS; 2016 Jan; 30(1):57-63. PubMed ID: 26372481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
    Yee KL; DiBenedetto A; Fan L; Khalilieh S; Triantafyllou I; Vallee MH; Fackler P; Stoch SA; Iwamoto M
    AAPS PharmSciTech; 2020 Feb; 21(3):91. PubMed ID: 32060665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
    Feng M; Sachs NA; Xu M; Grobler J; Blair W; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2241-7. PubMed ID: 26833152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doravirine: its role in HIV treatment.
    Stockdale AJ; Khoo S
    Curr Opin HIV AIDS; 2022 Jan; 17(1):4-14. PubMed ID: 34740228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Scheibe K; Urbańska A; Jakubowski P; Hlebowicz M; Bociąga-Jasik M; Raczyńska A; Szymczak A; Szetela B; Łojewski W; Parczewski M
    Antivir Ther; 2021 May; 26(3-5):69-78. PubMed ID: 35485331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV.
    Ciccullo A; Baldin G; Putaggio C; Di Giambenedetto S; Borghetti A
    Expert Opin Drug Saf; 2021 Nov; 20(11):1317-1332. PubMed ID: 34018892
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model.
    Zizioli D; Ferretti S; Tiecco G; Mignani L; Monti E; Castelli F; Quiros-Roldan E; Zanella I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
    Lam E; Schaefer J; Zheng R; Zhan T; Kraft WK
    Clin Transl Sci; 2020 Nov; 13(6):1244-1250. PubMed ID: 32407548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.